FDA releases BPA report
This article was originally published in The Tan Sheet
Executive Summary
FDA releases the draft report on the safety of bisphenol-A in plastics related to food contact applications on Aug. 15, ahead of the Sept. 16 meeting of the BPA subcommittee of FDA's science board. The BPA subcommittee will meet at the Hilton Washington in Rockville, Md., to discuss the draft assessment of BPA for use in food contact applications, according to a same-day Federal Register notice. The subcommittee will also hear oral presentations from members of the public, the notice says. Chief Scientific Officer Frank Torti requested the BPA subcommittee's meeting and discussion of the FDA Task Force BPA report in early June (1"The Tan Sheet" June 9, 2008, In Brief)...
You may also be interested in...
FDA chief scientist wants BPA review
At the request of newly appointed FDA Chief Scientist Frank M. Torti, a new Science Board subcommittee will hold a public meeting on the safety of bisphenol-A in plastics, review an FDA Task Force report on BPA and deliver its findings to the Science Board's annual meeting in the fall, according to a June 6 FDA release. The Task Force will make recommendations to Commissioner Andrew von Eschenbach following its review. Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Oversight and Investigations Subcommittee Chairman Bart Stupak in April asked FDA to reconsider BPA's safety in infant products (1"The Tan Sheet" April 12, 2008, In Brief)...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.